Will Kamada stock go up?

According to Danelfin AI, Kamada has today an AI Score of 6/10 (Hold rating), because its probability of beating the market in 3 months (56.32%) is +5.51% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Kamada stock?

The Kamada target price is $13.5 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Kamada stock right now?

Kamada has today a Hold rating (AI Score 6/10), according to Danelfin AI. Its probability of beating the market in 3 months (56.32%) is +5.51% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Kamada stock is a good buy .

Is Kamada undervalued right now?

Based on analysts, the average price target upside for Kamada is +79.06% (1Y). According to Danelfin AI, Kamada has today an AI Score of 6/10 (Hold Rating).

What was the price range of Kamada stock over the past 12 months?

The Kamada stock price range over the past 12 months has been $6.6 - $9.31.

What is going on with Kamada stock in the last 3 months?

The Kamada stock performance in the last quarter has been -9.59%.

Does Kamada offer dividend payments?

Yes, Kamada stock dividend yield is 3.32%.

What is the current market capitalization of Kamada?

Kamada's market cap is $433.83M, as of 2026-07-02 08:00.

When is the next KMDA earnings report date?

KMDA will publish its next earnings report on 2026-05-13.

Kamada Ltd (KMDA) AI Stock Analysis

Advanced Chart

Custom range

Jul 2, 2025

→

Jul 2, 2026

Custom range

Jul 2, 2025

→

Jul 2, 2026

KMDA AI-Powered Stock Analysis

AI Score Explanation

AI Score

Hold

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Kamada Ltd today receives an AI Score of 6/10, which translates to a Hold rating. The stock has a 56% probability of outperforming the market in the next 3 months, which is 5% higher than the average probability of any stock (51%). Key positive contributors include the long tail of fundamentals impact (+3.43%), low short float at 0.36% (bottom 10%), the Biotechnology industry (+0.60%), a low forward P/E of 11.84 (bottom 40%), and the Israel country factor (+0.39%). On the negative side, detractors include Net PP&E of $41.46M (bottom 50%, -0.60%), a bearish 504-day chart pattern (-0.47%), a 90-day chart pattern (-0.26%), and low institutional ownership at 14.71% (bottom 30%, -0.25%). Notable data points include an operating profit margin of 15.37% (top 30%), which signals strong operational efficiency, and an analyst lowest price upside of 61.12% (top 20%), indicating significant potential even from the most conservative estimate. However, the negative operating cash flow of -$0.29M (bottom 40%) and low institutional ownership weigh on the outlook. Overall, the stock's probability is slightly above average, supported by valuation and industry tailwinds, but tempered by weak cash flow and technical patterns, justifying the neutral HOLD rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

Valuation+3.95%
How the stock is priced relative to its fundamentals
Sentiment+0.99%
How analysts and the market view the stock
Volatility+0.56%
How much the stock price tends to fluctuate
Earnings Quality+0.35%
Stability and reliability of reported earnings
Size & Liquidity+0.34%
Company size and trading liquidity
Profitability+0.28%
Profitability and operating efficiency metrics

Momentum-0.74%
Direction and strength of recent price movements
Financial Strength-0.22%
Balance sheet strength and financial resilience

KMDA probability advantage of beating the market (3M):

+5.51%

AI Score

Hold

Kamada (KMDA) has an AI Score of 6/10 (Hold) because, according to an overall analysis, it has a probability advantage of +5.51% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of KMDA (56.32%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
KMDA probability advantage of beating the market (3M)+5.51%
KMDA probability of beating the market (3M)56.32%

KMDA probability advantage of beating the market (3M): +5.51%

The AI-powered overall analysis of Kamada (KMDA) is based on the 27 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of KMDA:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	+3.43%
Sentiment	Short Float (%)	0.36%	N/A	+0.63%
Sentiment	Industry (GICS)	Biotechnology	N/A	+0.60%
Fundamental	Net Property, Plant & Equipment (Net PP&E)	41.46		-0.60%
Technical	Chart Pattern (504d)	figure_87	N/A	-0.47%
Fundamental	Forward Price-to-Earnings	11.84%		+0.39%
Sentiment	Country	Israel	N/A	+0.39%
Fundamental	Operating Cash Flow (Qtr Discrete)	-0.29		+0.35%
Fundamental	Beginning Cash (Millions)	75.47		+0.34%
Technical	Beta	0.88		+0.31%
Technical	Upgrade to unlock			+0.30%
Sentiment	Upgrade to unlock			+0.29%
Fundamental	Upgrade to unlock			+0.28%
Technical	Upgrade to unlock			+0.27%
Technical	Upgrade to unlock			-0.26%

Rest of Alpha Signals: -0.71%

KMDA probability advantage of beating the market (3M)Total:+5.51%
KMDA AI Score

Significant changes Vs previous day

KMDA Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$7.54
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

KMDA Proven Hold Signal & Price Forecast

This is the price chart for KMDA from January 1, 2026 until today. The chart indicates, in yellow, the 67 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

KMDA Average Past Performance & Win Rate

Three months after its 1619 Hold signals since July 2026, KMDA had an average performance of xxxxxx and a xxxxxx Win rate (positive performance).

1619 Past KMDA Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				+8.41%
Average Alpha				-5.09%
Win Rate (% Positive Perf.)				62.22%
% Positive Alpha				42.09%

KMDA Frequently Asked Questions

Will Kamada stock go up?
According to Danelfin AI, Kamada has today an AI Score of 6/10 (Hold rating), because its probability of beating the market in 3 months (56.32%) is +5.51% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Kamada stock?
Is it a good time to buy, sell, or hold Kamada stock right now?
Is Kamada undervalued right now?
What was the price range of Kamada stock over the past 12 months?
What is going on with Kamada stock in the last 3 months?
Does Kamada offer dividend payments?
What is the current market capitalization of Kamada?
When is the next KMDA earnings report date?

Kamada Ltd Company Profile

Renowned for its unique specialization in the realm of protein therapeutics derived from plasma, Kamada Ltd. has made a significant mark in the healthcare industry with a diverse portfolio of life-changing products. Its hallmark product lineup includes KAMRAB/KEDRAB utilized for rabies prophylaxis and CYTOGAM, pivotal in curtailing Cytomegalovirus disease across multiple organ transplants like kidneys, lungs, liver, pancreas and heart.

Boosting their robust product range is VARIZIG which caters to varicella post exposure prophylaxis and WINRHO SDF adjustment to immune thrombocytopenic purpura and rhesus isoimmunization suppression. Furthermore, HEPAGAM B serves as a preventive measure against hepatitis B reoccurrence post liver transplants while GLASSIA effectively fulfills intravenous AATD needs.

Kamada Ltd.'s noteworthy ventures include the development of Antiserum for snake bites — Echis coloratus and Vipera palaestinae. Moreover, they have progressed into effective treatment areas such as bronchial airway hyperactivity diagnosis (PROVOCHOLINE), chronic obstructive pulmonary disease (TRIMBOW), asthma (FOSTER) and chronic pulmonary infection (BRAMITOB).

In Israel, they expanded their reach by distributing imported drugs catering to a spectrum of health conditions ranging from rheumatoid arthritis to hemophilia types A & B. They also distribute COAGADEX serving individuals with hereditary factor X deficiency and LAMZEDE for alpha-mannosidosis patients among other medicinal products for various conditions.

The company's journey began in 1990, setting down its roots in Rehovot, Israel where it continues to function as the operational nerve center today. From formulating remedies for immunity-related conditions to pioneering cures for multiple cancers including prostate, Kamada Ltd. maintains its instrumental presence in the medical field.

Sector:Health Care
Country:Israel
Industry:Biotechnology
Address:2 Holtzman St., Science Park, Rehovot
Employees:393
Website:kamada.com

Pros

Niche market focus for plasma-derived therapeutics

High regulatory barriers to entry in biopharmaceuticals

Established global distribution network for specialty drugs

Recurring demand for essential plasma-derived medicines

Vertical integration in plasma collection and fractionation

Cons

Dependency on consistent plasma supply chain

Extensive capital expenditure for manufacturing facilities

Competition from larger biopharmaceutical companies

Revenue concentration in a limited product portfolio

Long development cycles for new plasma-derived therapies

Company	AI Score	Compare
ADMAADMA Biologics Inc
TAKTakeda Pharmaceutical Co Ltd
AKANAkanda Corp
DMACDiaMedica Therapeutics Inc
GDTCCytoMed Therapeutics Ltd

Company	AI Score	Compare
ADMAADMA Biologics Inc
TAKTakeda Pharmaceutical Co Ltd
AKANAkanda Corp
DMACDiaMedica Therapeutics Inc
GDTCCytoMed Therapeutics Ltd

KMDA Stock AI Analysis

Kamada Ltd

KMDA Stock AI Analysis

Kamada Ltd

KMDA AI-Powered Stock Analysis

AI Score Explanation

AI Score Explanation

Generating AI Score explanation

AI Score Alpha Factors

Alpha Signals: What Drives the AI Score

KMDA probability advantage of beating the market (3M): +5.51%

KMDA Trading Parameters

KMDA Proven Hold Signal & Price Forecast

KMDA Average Past Performance & Win Rate

KMDA Frequently Asked Questions

Will Kamada stock go up?

What is the target price for Kamada stock?

Is it a good time to buy, sell, or hold Kamada stock right now?

Is Kamada undervalued right now?

What was the price range of Kamada stock over the past 12 months?

What is going on with Kamada stock in the last 3 months?

Does Kamada offer dividend payments?

What is the current market capitalization of Kamada?

When is the next KMDA earnings report date?

Kamada Ltd Company Profile

Pros

Cons

Pros

Cons

KMDA Company Profile Summary

KMDA Related Investment Themes

KMDA Related Stocks

KMDA Top 10 Industry Stocks

Biotechnology

KMDA Top 10 Sector Stocks

Health Care

KMDA Stock AI Analysis

Kamada Ltd

NASDAQ NMS - GLOBAL MARKET

Will Kamada stock go up?

What is the target price for Kamada stock?

Is it a good time to buy, sell, or hold Kamada stock right now?

Is Kamada undervalued right now?

What was the price range of Kamada stock over the past 12 months?

What is going on with Kamada stock in the last 3 months?

Does Kamada offer dividend payments?

What is the current market capitalization of Kamada?

When is the next KMDA earnings report date?

Pros

Cons

AI Score Explanation

NASDAQ NMS - GLOBAL MARKET

KMDA Proven Hold Signal & Price Forecast